

WHAT IS CLAIMED IS:

1. A monoclonal antibody comprising a monoclonal antibody having an ability to bind to an SCF receptor.
2. A monoclonal antibody according to claim 1 wherein said SCF receptor is a human SCF receptor.
3. A monoclonal antibody according to claim 2 wherein said monoclonal antibody is SR-1.
4. A monoclonal antibody according to claim 1 further comprising an ability to inhibit binding of a SCF molecule to said SCF receptor.
5. A monoclonal antibody according to claim 4 wherein said SCF molecule is a human SCF molecule.
6. A monoclonal antibody according to claim 5 wherein said SCF receptor is a human SCF receptor.

(a) exposing a mixture of cells to a monoclonal antibody according to claim 1;

8. A method of purifying hematopoietic cells
10 according to claim 7 wherein said separating is by
column chromatography.

10. A method of purifying hematopoietic cells according to claim 7 wherein said separating is by direct immune adherence.

25

5 13. A method of separating normal cells from
neoplastic leukemia cells comprising the steps of:

10 (b) separating normal cells from neoplastic leukemia cells based upon a differential in numbers of SCF receptors on normal cells and neoplastic leukemia cells.

20 15. A method of treating leukemia cells
comprising administration of a therapeutically effective
amount of a leukemia therapeutic agent conjugated to a
binding fragment of a monoclonal antibody according to
claim 1.

25

5

10

15

15

20

25

21. A method of modifying sensitivity to cell cycle-specific chemotherapeutic agents comprising administration of a SCF inhibiting amount of a monoclonal antibody according to claim 1.

5

22. A monoclonal antibody according to claim 1 wherein said monoclonal antibody is a murine-human hybrid antibody.

10

23. A monoclonal antibody according to claim 1 wherein said antibody is of the IgG2a isotype.

24. A hybridoma capable of producing a monoclonal antibody according to claim 1.

15

25. A hybridoma according to claim 24 wherein said hybridomas is capable of producing the monoclonal antibody SR-1.

Handwritten signature and initials.

666720 9912460